Barry Ticho Sells 2,586 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,586 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $33,592.14. Following the completion of the transaction, the insider now owns 44,746 shares in the company, valued at approximately $581,250.54. This represents a 5.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Barry Ticho also recently made the following trade(s):

• On Friday, December 6th, Barry Ticho sold 13,945 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.78, for a total value of $178,217.10.
• On Monday, December 2nd, Barry Ticho sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $12.07, for a total value of $120,700.00.

Stoke Therapeutics Trading Down 5.1 %

Shares of STOK stock opened at $12.32 on Friday. Stoke Therapeutics, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.58. The stock has a 50 day moving average price of $12.48 and a two-hundred day moving average price of $13.67.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. On average, analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently modified their holdings of the business. Quest Partners LLC bought a new position in Stoke Therapeutics in the 2nd quarter worth about $29,000. Nisa Investment Advisors LLC increased its stake in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Stoke Therapeutics in the second quarter worth about $123,000. Intech Investment Management LLC bought a new position in shares of Stoke Therapeutics in the third quarter worth approximately $160,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares in the last quarter.

Wall Street Analyst Weigh In

STOK has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.